What is Leerink Partnrs’ Estimate for ACRS FY2024 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Thursday, November 7th. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings per share of ($0.63) for the year, down from their prior forecast of ($0.26). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.67) per share. Leerink Partnrs also issued estimates for Aclaris Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.55) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.39) EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 7th. HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.00.

Aclaris Therapeutics Stock Down 0.4 %

Shares of NASDAQ ACRS opened at $2.63 on Monday. The stock’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.26. Aclaris Therapeutics has a one year low of $0.59 and a one year high of $2.68.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC boosted its position in Aclaris Therapeutics by 9.7% in the third quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after buying an additional 1,261,866 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Aclaris Therapeutics by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after acquiring an additional 207,418 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Aclaris Therapeutics by 1.9% during the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock valued at $3,671,000 after acquiring an additional 63,358 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Aclaris Therapeutics during the 2nd quarter worth $2,120,000. Finally, Trium Capital LLP increased its holdings in Aclaris Therapeutics by 1.1% in the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock worth $2,200,000 after purchasing an additional 20,940 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.